FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105961004> ?p ?o ?g. }

• W2105961004 endingPage "263" @default.
• W2105961004 startingPage "263" @default.
• W2105961004 abstract "Research progress on criteria for discontinuation of EGFR inhibitor therapy Hong-qing Zhuang, Zhi-yong Yuan, Jun Wang, Ping Wang, Lu-jun Zhao, Bai-lin ZhangDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin, People&#39;s Republic of ChinaAbstract: The clinical success of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as therapeutic agents has prompted great interest in their further development and clinical testing for a wide variety of malignancies. However, most studies have focused on the efficacy of TKI, and few studies have been done on the criteria for their discontinuation. The current standard for drug discontinuation is “until progression”, based on change in tumor size. However, tumor size is not related to the gene expression which determines the efficacy of TKI in the final analysis, and it is also difficult to make a thorough and correct prediction based on tumor size when the TKI is discontinued. Nevertheless, clinical evaluation of the criteria for TKI discontinuation is still in its early days. Some promising findings have started to emerge. With the improving knowledge of EGFR and its inhibitors, it is expected that the criteria for discontinuation of EGFR inhibitor therapy will become clearer.Keywords: epidermal growth factor receptor, drug discontinuation, acquired drug-resistance" @default.
• W2105961004 created "2016-06-24" @default.
• W2105961004 creator A5013736647 @default.
• W2105961004 creator A5018258401 @default.
• W2105961004 creator A5023907849 @default.
• W2105961004 creator A5056569407 @default.
• W2105961004 creator A5057417537 @default.
• W2105961004 creator A5058625421 @default.
• W2105961004 date "2012-10-01" @default.
• W2105961004 modified "2023-09-26" @default.
• W2105961004 title "Research progress on criteria for discontinuation of EGFR inhibitor therapy" @default.
• W2105961004 cites W1523413020 @default.
• W2105961004 cites W1557061959 @default.
• W2105961004 cites W1848898216 @default.
• W2105961004 cites W1931843124 @default.
• W2105961004 cites W1967249248 @default.
• W2105961004 cites W1978916359 @default.
• W2105961004 cites W1981262353 @default.
• W2105961004 cites W1982637165 @default.
• W2105961004 cites W1987797739 @default.
• W2105961004 cites W1988737089 @default.
• W2105961004 cites W1994816216 @default.
• W2105961004 cites W1998971866 @default.
• W2105961004 cites W2000514139 @default.
• W2105961004 cites W2000630926 @default.
• W2105961004 cites W2001155346 @default.
• W2105961004 cites W2005075550 @default.
• W2105961004 cites W2005631145 @default.
• W2105961004 cites W2009196090 @default.
• W2105961004 cites W2010022150 @default.
• W2105961004 cites W2013625828 @default.
• W2105961004 cites W2013678879 @default.
• W2105961004 cites W2015168722 @default.
• W2105961004 cites W2019573100 @default.
• W2105961004 cites W2020707154 @default.
• W2105961004 cites W2026727845 @default.
• W2105961004 cites W2030485399 @default.
• W2105961004 cites W2033351371 @default.
• W2105961004 cites W2034646571 @default.
• W2105961004 cites W2039633811 @default.
• W2105961004 cites W2041058556 @default.
• W2105961004 cites W2043696829 @default.
• W2105961004 cites W2045147990 @default.
• W2105961004 cites W2047826668 @default.
• W2105961004 cites W2050141745 @default.
• W2105961004 cites W2051408106 @default.
• W2105961004 cites W2056940735 @default.
• W2105961004 cites W2062889207 @default.
• W2105961004 cites W2068244265 @default.
• W2105961004 cites W2070241543 @default.
• W2105961004 cites W2070705072 @default.
• W2105961004 cites W2076414923 @default.
• W2105961004 cites W2077374035 @default.
• W2105961004 cites W2088947217 @default.
• W2105961004 cites W2092452653 @default.
• W2105961004 cites W2093613683 @default.
• W2105961004 cites W2103334409 @default.
• W2105961004 cites W2104743043 @default.
• W2105961004 cites W2105638105 @default.
• W2105961004 cites W2120718661 @default.
• W2105961004 cites W2121389354 @default.
• W2105961004 cites W2123343744 @default.
• W2105961004 cites W2128863123 @default.
• W2105961004 cites W2134989772 @default.
• W2105961004 cites W2142564546 @default.
• W2105961004 cites W2142865455 @default.
• W2105961004 cites W2143536404 @default.
• W2105961004 cites W2146404049 @default.
• W2105961004 cites W2150079073 @default.
• W2105961004 cites W2151808807 @default.
• W2105961004 cites W2153242757 @default.
• W2105961004 cites W2154497360 @default.
• W2105961004 cites W2154946742 @default.
• W2105961004 cites W2155384808 @default.
• W2105961004 cites W2157208434 @default.
• W2105961004 cites W2157824687 @default.
• W2105961004 cites W2158158704 @default.
• W2105961004 cites W2159013299 @default.
• W2105961004 cites W2159995951 @default.
• W2105961004 cites W2160249387 @default.
• W2105961004 cites W2160425081 @default.
• W2105961004 cites W2160511594 @default.
• W2105961004 cites W2161710468 @default.
• W2105961004 cites W2161821474 @default.
• W2105961004 cites W2161965319 @default.
• W2105961004 cites W2165593156 @default.
• W2105961004 cites W2168554121 @default.
• W2105961004 cites W2168841302 @default.
• W2105961004 cites W2169816570 @default.
• W2105961004 cites W2171875712 @default.
• W2105961004 cites W2410691869 @default.
• W2105961004 cites W2412926880 @default.
• W2105961004 cites W2479171025 @default.
• W2105961004 doi "https://doi.org/10.2147/ott.s36103" @default.
• W2105961004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3475392" @default.
• W2105961004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23082072" @default.
• W2105961004 hasPublicationYear "2012" @default.
• W2105961004 type Work @default.

• next